Table 1

Patient characteristics
Parameter Voriconazole Caspofungin Fluconazole     p-value for overall difference
n (%) 19 (14.8) 55 (43.0) 54 (42.2)
Age, Mean (SD) 61.7 (13.9) 63.9 (13.9) 63.7 (14.7) 0.83
Male, n (%) 10 (52.6) 34 (61.8) 20 (37.0) 0.03
White, n (%) 17 (89.5) 43 (78.2) 49 (90.7) 0.63
Length of treatment (days)
 Mean (SD) 8.1 (6.3) 8.6 (5.3) 9.8 (9.8) 0.62
 Median (IQR) 6.0 (4–12) 7.0 (5–11) 8.0 (5–11) 0.53
 Min, Max 2, 29 2, 27 2, 74 NS
Comorbidities: Diabetes mellitus, hypertension or nephropathy, n (%) 11 (57.9) 46 (83.6) 43 (79.6) 0.06
Underlying condition, n (%) 0.001
 Cancer 12 (63)* 7 (13) 13 (24)
 HIV 0 0 1
 ICU 15 (79) 31 (56) 26 (48)
 Immunosuppression** 12 (63) 3 (5) 12 (22)
 More than 1 underlying condition 12 (63) 9 (16) 16 (30)
Concomitant nephrotoxic agent, n (%) 14 (73.7) 31 (56.4) 27 (50.0) 0.20
Underlying fungal disease, n (%)* 0.002
Candida spp. 5 (55.6) 43 (93.5) 39 (92.9)
Aspergillus spp. 4 (44.4) 3 (6.5) 3 (7.1)
Indication for antifungal therapy, n (%) NS
 Prophylaxis 10 (53) 8 (15) 5 (9)
 Empiric 0 1 (2) 5 (9)
 Presumed or Confirmed 9 (47) 46 (84) 42 (78)

*10 patients with AML were treated with voriconazole prophylaxis.

**Chemotherapy, transplant rejection prevention or treatment, ≥ 1 mg/kg prednisone.

Cases were included only when an Infectious Diseases consultant determined that the isolate represented an infection rather than colonization.

Lilly et al.

Lilly et al. BMC Infectious Diseases 2013 13:14   doi:10.1186/1471-2334-13-14

Open Data